EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Ahmet Yildirim, Jillian C. Thompson, Umut Akova, Yash Jani, Caitlin Hartman, Greta R. McClintock, Sarah E. Caulfield, Shahid S. Ahmed, Jacob E. Berchuck, Jordan A. Ciuro, Bassel Nazha, Jacqueline T. Brown und 5 weitere

Journal of Immunotherapy and Precision Oncology · 2027-02 · 10 (1) · 20-28

DOI: 10.36401/jipo-26-13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, 2027-02. Verfasst von Ahmet Yildirim und 16 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Concomitant medications such as statins, aspirin, and metformin may modulate immune responses and influence outcomes with immune checkpoint inhibitors (ICIs). Their impact in advanced renal cell carcinoma (aRCC) remains unclear.

Methods

We conducted a retrospective study of 400 patients with aRCC treated with ICIs at Winship Cancer Institute of Emory University from 2018 to 2023. Baseline medication use, defined as active prescription at the time of ICI initiation, was documented. Clinical end points included overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Kaplan-Meier estimates, Cox proportional hazards models, and multivariable regression were used to assess associations between medication use and outcomes.

Results

At baseline, 42.5% of patients were on statins, 34.5% on aspirin, and 12.3% on metformin. Median follow-up was 43.0 months. Statin use was associated with improved DCR (odds ratio, 1.85; p = 0.008), with a positive trend observed for PFS (hazard ratio [HR], 0.81; p = 0.071) in univariable analysis. However, no significant independent associations were observed in multivariable models for overall survival (HR, 0.92; p = 0.629), PFS (HR, 0.90; p = 0.410), or DCR (odds ratio, 1.48; p = 0.119). Aspirin and metformin use were not significantly associated with outcomes in univariable analyses and were excluded from multivariable models.

Conclusion

In this large real-world cohort, concomitant statin, aspirin, and metformin use did not independently influence survival or response outcomes in patients with aRCC receiving ICIs. Although statin use was univariably associated with a higher disease control rate, this effect did not persist after multivariable adjustment. These findings indicate that these common medications are unlikely to have a strong independent impact on immunotherapy outcomes in this population. Graphical Abstract

Zitieren

APA

Yildirim, A., Thompson, J. C., Akova, U., Jani, Y., Hartman, C., McClintock, G. R., Caulfield, S. E., Ahmed, S. S., Berchuck, J. E., Ciuro, J. A., Nazha, B., Brown, J. T., Carthon, B. C., Kucuk, O., Liu, Y., Master, V. A., & Bilen, M. A. (2027). Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 10(1), 20-28. https://doi.org/10.36401/jipo-26-13

Vancouver

Yildirim A, Thompson JC, Akova U, Jani Y, Hartman C, McClintock GR, et al. Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology. 2027;10(1):20-28. doi:10.36401/jipo-26-13

BibTeX
@article{Yildirim2027,
  author = {Yildirim, Ahmet and Thompson, Jillian C. and Akova, Umut and Jani, Yash and Hartman, Caitlin and McClintock, Greta R. and Caulfield, Sarah E. and Ahmed, Shahid S. and Berchuck, Jacob E. and Ciuro, Jordan A. and Nazha, Bassel and Brown, Jacqueline T. and Carthon, Bradley C. and Kucuk, Omer and Liu, Yuan and Master, Viraj A. and Bilen, Mehmet A.},
  title = {Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2027},
  volume = {10},
  number = {1},
  pages = {20--28},
  doi = {10.36401/jipo-26-13}
}
Kostenlos starten →